Literature DB >> 9169967

Selective serotonin reuptake inhibitor-induced serotonin syndrome: review.

R Lane1, D Baldwin.   

Abstract

The selective pharmacology of the selective serotonin reuptake inhibitors (SSRIs) results in a lower potential for pharmacodynamic drug interactions relative to other antidepressants such as the tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). However, the SSRIs have been implicated in the development of the serotonin syndrome--a potentially life-threatening complication of treatment with psychotropic drugs. The syndrome is produced most often by the concurrent use of two or more drugs that enhance central nervous system serotonin activity and often goes unrecognized because of the varied and nonspecific nature of its clinical features. The serotonin syndrome is characterized by alterations in cognition (disorientation, confusion), behavior (agitation, restlessness), autonomic nervous system function (fever, shivering, diaphoresis, diarrhea), and neuromuscular (ataxia, hyperreflexia, myoclonus) activity. The difference between this syndrome and the occurrence of adverse effects caused by serotonin reuptake inhibitors alone is the clustering of the signs and symptoms, their severity, and their duration. There are important pharmacokinetic interactions between SSRIs and other serotonergic drugs due principally to their effects on the cytochrome P450(CYP) isoenzymes, the potential for which varies widely amongst the SSRI group, which may increase the likelihood of a pharmacodynamic interaction. The exceptionally long washout period required after fluoxetine discontinuation may cause additional problems and/or inconvenience. Patients with serotonin syndrome usually respond to discontinuation of drug therapy and supportive care alone, but they may also require treatment with antiserotonergic agent such as cyproheptadine, methysergide, and/or propranolol. To reduce the occurrence, morbidity, and mortality of the serotonin syndrome, it must be both prevented by prudent pharmacotherapy and given prompt recognition when it is present.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9169967     DOI: 10.1097/00004714-199706000-00012

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  29 in total

Review 1.  ["Clinically significant" new drug interactions].

Authors:  U Fuhr
Journal:  Med Klin (Munich)       Date:  1999-02-15

Review 2.  Fortnightly review: drug treatment of depression.

Authors:  O Spigset; B Mårtensson
Journal:  BMJ       Date:  1999-05-01

Review 3.  Serotonin syndrome: a brief review.

Authors:  Philippe Birmes; Dominique Coppin; Laurent Schmitt; Dominique Lauque
Journal:  CMAJ       Date:  2003-05-27       Impact factor: 8.262

4.  Brain dopamine and serotonin differ in regulation and its consequences.

Authors:  Parastoo Hashemi; Elyse C Dankoski; Rinchen Lama; Kevin M Wood; Pavel Takmakov; R Mark Wightman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

5.  Clomipramine induced neuroleptic malignant syndrome and pyrexia of unknown origin.

Authors:  Alison M Haddow; Dawn Harris; Martin Wilson; Hannah Logie
Journal:  BMJ       Date:  2004-12-04

Review 6.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

7.  Decynium-22 enhances SSRI-induced antidepressant-like effects in mice: uncovering novel targets to treat depression.

Authors:  Rebecca E Horton; Deana M Apple; W Anthony Owens; Nicole L Baganz; Sonia Cano; Nathan C Mitchell; Melissa Vitela; Georgianna G Gould; Wouter Koek; Lynette C Daws
Journal:  J Neurosci       Date:  2013-06-19       Impact factor: 6.167

8.  Medicine Cabinet: Drug treatment of depression.

Authors:  B Martensson; O Spigset
Journal:  West J Med       Date:  1999-08

9.  Serotonin syndrome with paroxetine overdose: a case report.

Authors:  Fatih Canan; Ugur Korkmaz; Emel Kocer; Elif Onder; Salih Yildirim; Ahmet Ataoglu
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

10.  The Food and Drug Administration's deliberations on antidepressant use in pediatric patients.

Authors:  Laurel K Leslie; Thomas B Newman; P Joan Chesney; James M Perrin
Journal:  Pediatrics       Date:  2005-07       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.